| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO | /s/ Srinivas Akkaraju | 06 May 2025 | 0001253170 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALMS | Common Stock | Purchase | $727,636 | +159,920 | +4.9% | $4.55 | 3,426,418 | 02 May 2025 | By Samsara BioCapital, L.P. | F1, F2 |
| transaction | ALMS | Common Stock | Purchase | $633,725 | +138,368 | +4% | $4.58 | 3,564,786 | 05 May 2025 | By Samsara BioCapital, L.P. | F2, F3 |
| transaction | ALMS | Common Stock | Purchase | $115,951 | +22,002 | +0.62% | $5.27 | 3,586,788 | 05 May 2025 | By Samsara BioCapital, L.P. | F2, F4 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.97 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |
| F2 | Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.19 to $5.1899 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $5.19 to $5.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |